IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

John G. Babish, et al.

Application No:

10/557,293

Confirmation No.:

9021

Art Unit:

1655

Filed:

December 20, 2006

Title:

ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR

REDUCING INFLAMMATION AND THE TREATMENT OR

PREVENTION OF GASTRIC TOXICITY

Docket No.:

068911-0126

Z162321813212 Z1 Z16182 ZNE119183 X XLCCXZNZNA

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 or filed via EFS-Web to the USPTO, on the date indicated below.

Date: August 31, 2010

Acquelin Andreu

MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT OF ENTITY STATUS CHANGE NOTIFICATION UNDER 37 CFR § 1.27(g)(2)

The assignee of the above-referenced patent application now qualifies as a LARGE entity and the small entity status is no longer applicable. The Issue Fee Transmittal reflecting the changes in the entity status is concurrently filed with this notification. The Commissioner is hereby authorize to charge LARGE ENTITY fees for issue fee payment, any deficiency, or credit any overpayment, to deposit Account Number 50-1133. If you have any questions regarding this matter, please contact the undersigned.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Date: August 31, 2010

Atabak R. Royaee, Ph.D.

Registration No. 59,037

28 State Street

Boston, MA 02109 – 1775 Telephone: 617-535-4108

Facsimile: 617-535-3800